Search
Without access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
Hematology in the spotlight at EAPM Presidency Conference
April 9, Brussels - The European Alliance for Personalised Medicine is holding its 7th annual presidency conference at the University Foundation in Brussels, and the event will include a session on Hematology - Personalised treatment and personalised prevention.
Read moreGAPP Joint Action
Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.
Read moreMadrid Declaration: joint call for action on training requirements
The Madrid Declaration on enhanced training requirements for hematologists in the Professional Qualifications Directive enjoyed broad support from national society representatives at the EHA22 National Societies Dinner in Madrid.
Read moreABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.
Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.
Read moreLeading Medical Organizations Join Forces Globally to Launch First-Ever World Thrombosis Day
“We must reduce the burden from thrombosis if we are to achieve the World Health Assembly’s global target of reducing mortality from premature non-communicable disease by 25 percent by 2025,” said Gary Raskob, Ph. D.
Read moreDaratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.
Read morePersonalized medicine promises radical improvements to healthcare in Europe
And the precision that personalised medicine will bring good prospects for better use of resources.
Read more